The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 16, 2025

Filed:

Feb. 14, 2022
Applicant:

Meiragtx Gene Regulation Limited, London, GB;

Inventors:

Alex R. Boyne, Jersey City, NJ (US);

Olivier F. Danos, New York, NY (US);

Michael J. Volles, Cambridge, MA (US);

Xuecui Guo, Oyster Bay, NY (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 9/00 (2006.01); A61K 38/44 (2006.01); A61K 48/00 (2006.01); C12N 9/06 (2006.01); C12N 15/115 (2010.01); C12N 15/63 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61K 9/0048 (2013.01); A61K 38/44 (2013.01); A61K 48/0033 (2013.01); A61K 48/0066 (2013.01); A61K 48/0075 (2013.01); C12N 9/003 (2013.01); C12N 15/115 (2013.01); C12N 15/63 (2013.01); C12Y 105/01003 (2013.01); C12N 2310/16 (2013.01); C12N 2310/3519 (2013.01); C12N 2320/32 (2013.01); C12N 2320/33 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14171 (2013.01); C12N 2840/002 (2013.01); C12N 2840/44 (2013.01);
Abstract

The invention provides a platform and methods of using the platform for the regulation of the expression of a target gene using exposure to an aptamer ligand (for example, a small molecule). The platform features a polynucleotide gene regulation cassette that is placed in the target gene and includes a synthetic riboswitch positioned in the context of a 5' intron-alternative exon-3′ intron. The riboswitch comprises an effector region and a sensor region (e.g., an aptamer that binds a small molecule ligand) such that the alternative exon is spliced into the target gene mRNA when the ligand is not present thereby preventing expression of the target gene. When the ligand is present, the alternative exon is not spliced into the target gene mRNA thereby providing expression of the target gene.


Find Patent Forward Citations

Loading…